Cardiovascular Diagnosis and Therapy Special Issue · Full Text

Transcatheter Aortic Valve Replacement in Preserved Left Ventricular Function: Mapping Paradoxical Changes in Diastolic Function and LV Regression

, ,

1Department of Internal Medicine, Allegheny General Hospital, USA
2Department of Cardiovascular Disease, Allegheny General Hospital, USA

Article Information

Clinics Cardiology, Volume 1, Issue 2, Pages 1–3
Received: December 06, 2018
Accepted: December 17, 2018
Published: December 20, 2018
Citation copied successfully.

Abstract

Aortic stenosis (AS) is a high-afterload state, often leading to compensatory left ventricular (LV) hypertrophy and diastolic dysfunction due to long term microscopic and macroscopic adaptive changes. The impact of surgical aortic valve replacement (SAVR) has traditionally been well studied in this patient population, with reports showing improved hemodynamics, diastology and LV regression post surgical correction. The
corresponding effects have not been adequately mapped amongsimilar patients undergoing transcatheter aortic valve replacement (TAVR). Herein, we report a case that traces the paradoxical changes that occur in both diastolic function and LV regression in a patient after TAVR. Thereafter, we correlate the physiologic findings with the oft understudied microscopic and reverse adaptive changes post valve replacement.

Keywords

TAVR diastolic heart failure LV remodeling reverse remodeling LV hypertrophy

Introduction

Aortic stenosis (AS) is a high-after load state, often leading to compensatory left ventricular (LV) hypertrophy and diastolic dysfunction [1]. Studies in patients with severe AS have demonstrated adaptive microscopic changes, with progressive cardiomyocyte hypertrophy, extracellular matrix (ECM) expansion and interstitial fibrosis caused by collagen deposition [2,3]. The impact of surgical aortic valve replacement (SAVR) on these microscopic as well as macroscopic changes has been well reported. While normalization of LV hypertrophy is not seen among these patients, they typically undergo considerable LV regression with concordant improvement in diastolic function post procedure [4-6]. The extent and sustainability of these changes is largely unknown in patients with pure AS undergoing transcatheter aortic valve replacement (TAVR). Given the increased utilization of TAVR in the management of patients with severe AS and improved survival, there is emerging interest if similar effects on diastolic function are seen among these patients. Herein, we review a patient with severe AS who underwent TAVR and correlate the effects of TAVR on LV remodeling and diastolic function overtime, compared to the changes expected in patients undergoing SAVR.

Case Presentation

An 81 year-old female patient with severe symptomatic aortic stenosis presented for TAVR evaluation to our institution, due to an elevated surgical risk. Pre-operative transthoracic echocardiogram (TTE) confirmed the severity of AS and impaired diastolic function (Table 1). She underwent transfemoral TAVR with a 23 mm Edwards Sapien 3 valve. She was discharged on post-operative day 2 with no complications. There was significant improvement in the diastology parameters at one month post-TAVR, along with improvement in LVH as seen by decrease in LV mass index, interventricular septum and posterior wall thickness (Table 1). However, comparative TTE at one year revealed lack of sustenance of these changes with reversal of the initially favorable findings (Figure 1).

/article/view/images/img_1779880927_838a883e.png

Figure 1: Left ventricular reverse remodeling overtime post-TAVR. Note: A) Indexed LV mass; B) Indexed LV diastolic (dashed line) and systolic (solid line) volume; C) E/e’ ratio; D) Lateral (dashed line) and septal (solid line) e’.

Table 1: Changes overtime after TAVR by transthoracic echocardiography.

TTE parameters

Baseline TTE

1 month post-operative TTE

1 year post-operative TTE

Aortic valve

Valve area (cm2)

0.84

1.6

1

Mean gradient (mmHg)

51

17

10.5

Peak AV velocity (cm/s)

465

240.5

214

Dimensionless index

0.25

0.71

0.55

LV ejection fraction (%)

70-74

>75

>75

LV diastolic function

Grade of diastolic dysfunction

2

Indeterminate

2

MV E/A

0.9

0.4

0.8

MV E velocity (cm/s)

122

65.3

106.3

MV E/e’

40.67

32.65

34.29

MV septal e’ (cm/s)

3

2

3.1

MV lateral e’ (cm/s)

7.3

6

6.2

LAVI (mL/m2)

59.3

22.3

29

TR velocity (cm/s)

323.3

246.6

287

Aortic regurgitation

None

None

Trace

Mitral regurgitation

Mild

Trace

None

LV Volumetrics

LV systolic volume index (mL/m2)

15.7

7.7

10

LV diastolic volume index (mL/m2)

54.3

21.8

30.2

LV end-diastolic diameter (cm)

3.8

4.1

4.4

LV end-systolic diameter (cm)

2.1

2.5

3

Interventricular septum (cm)

1.6

1.4

1.2

Posterior wall (cm)

1.1

1.4

1.4

LV mass index (g/m2)

131

104

107

Pulmonary artery systolic pressure (mm Hg)

54

27

36

Note: AV, aortic valve; LAVI, left atrial volume index; LV, left ventricle; MV, mitral valve; TR, tricuspid regurgitation; TTE, transthoracic echocardiogram.

Discussion

Patients with AS have a fixed, high-afterload state with resultant LV remodeling due to myocardial hypertrophy, ECM expansion and interstitial fibrosis [2,3]. These structural changes consequentially cause hemodynamic derangement and diastolic function impairment [4,7]. Studies in patients with severe AS undergoing SAVR have demonstrated a favorable improvement in LV volumetrics with sequential histologic and imaging analyses showing LV regression within 6 months post procedure [5,6,8-11]. It is unknown if similar effects are seen in TAVR patients given the smaller valve sizes and higher mean gradients post-operatively.

In our case, despite several parameters of diastolic function demonstrating improvement in the immediate post-TAVR period, this improvement was not sustained at one year, revealing a lack of durability of the LV remodeling and diastology changes seen post-TAVR. There are multiple proposed mechanisms to explain these findings. One potential mechanism is nullification of the relief in valvular afterload by post procedural increase in supra valvular afterload in the form of arterial hypertension [12]. Another mechanism explaining the return of diastolic dysfunction at one year is the temporally disproportionate microscopic adaptive changes post procedure. Classically, the LV hypertrophic process is thought to be composed chiefly of sarcomeres laid down in parallel resulting in concentric hypertrophy. The hypertrophy is governed by sarcomere upregulation by increased mRNA activity as well as by collagen deposition and perimysial fiber increase by metal metalloproteinase (MMP’s) and tissue inhibitors of MMP’s (TIMP’s) activity. These signaling pathways presiding over myocytes and ECM are distinct and expressed at dissimilar rates resulting in asymmetrical LVH regression post-AVR. mRNA signaling following abrupt relief of afterload is halted immediately post procedure, in stark contrast to MMP activity which, inhibited by TIMP’s, is activated late and then incompletely [13,14]. The resultant effect is “accelerated” myocyte atrophy but with a more preserved interstitial composition that serves to hamper the expected regression of LVH [9]. Similar findings have been demonstrated in severe AS patients undergoing SAVR with serial cardiac MRI studies, where significant benefits in LV structure and function are noted up to 4 years post-SAVR, however still do not result in complete resolution of LVH and fibrosis, even in non hypertensive patients [6,9].

In summary, patients with severe AS undergoing SAVR experience a rapid, temporally relatable regression of LVH post surgery, with adjunct improvement in LV volumetrics and diastology. While the regression and hemodynamic correction is expected post TAVR as well, there is lack of durability of these changes. The case described above illustrates the paradoxical decline in LV diastolic function after an initial improvement post-TAVR due to inability of the microscopic adaptive changes to sustain themselves. More studies are needed on the long term trajectory of LV remodeling and diastology post TAVR along with clinical correlation of the same. This case is illustrative of the paradoxical temporal diastolic response post TAVR and should serve to remind the growing TAVR teams of this phenomenon.

How to Cite

Garima Dahiya, Andreas Kyvernitakis, Robert WW Biederman. Transcatheter Aortic Valve Replacement in Preserved Left Ventricular Function: Mapping Paradoxical Changes in Diastolic Function and LV Regression. Clinics Cardiology; 1(2):1–3.

References

1
Lorell BH, Carabello BA. Left ventricular hypertrophy: Pathogenesis, detection, and prognosis. Circulation. 2000; 102: 470-479.
URL: https://www.ncbi.nlm.nih.gov/pubmed/10908222
2
Azevedo CF, Nigri M, Higuchi ML et al. Prognostic significance of myocardial fibrosis quantification by histopathology and magnetic resonance imaging in patients with severe aortic valve disease. J Am Coll Cardiol. 2010; 56: 278-287.
URL: https://www.ncbi.nlm.nih.gov/pubmed/20633819
3
Weber KT, Sun Y, Tyagi SC, Cleutjens JP. Collagen network of the myocardium: Function, structural remodeling and regulatory mechanisms. J Mol Cell Cardiol. 1994; 26: 279-292.
URL: https://www.ncbi.nlm.nih.gov/pubmed/8028011
4
Villari B, Vassalli G, Monrad ES, Chiariello M, Turina M, Hess OM. Normalization of diastolic dysfunction in aortic stenosis late after valve replacement. Circulation. 1995; 91: 2353-2358.
5
Ali A, Patel A, Ali Z, Abu-Omar Y, Saeed A, Athanasiou T, et al. Enhanced left ventricular mass regression after aortic valve replacement in patients with aortic stenosis is associated with improved long-term survival. J Thorac Cardiovasc Surg. 2011; 142: 285-291.
URL: https://www.ncbi.nlm.nih.gov/pubmed/21272899
6
Treibel TA, Kozor R, Schofield R, Benedetti G, Fontana M, Bhuva AN, et al. Reverse myocardial remodeling following valve replacement in patients with aortic stenosis. J Am Coll Cardiol. 2018; 71: 860-871.
URL: https://www.ncbi.nlm.nih.gov/pubmed/29471937
7
Heymans S, Schroen B, Vermeersch P, Milting H, Gao F, Kassner A, et al. Increased cardiac expression of tissue inhibitor of metalloproteinase-1 and tissue inhibitor of metalloproteinase-2 is related to cardiac fibrosis and dysfunction in the chronic pressure-overloaded human heart. Circulation. 2005; 112: 1136-1144.
URL: https://www.ncbi.nlm.nih.gov/pubmed/16103240
8
Goncalves A, Marcos-Alberca P, Almeria C, Feltes G, Rodríguez E, Hernández-Antolín RA, et al. Acute left ventricle diastolic function improvement after transcatheter aortic valve implantation. Eur J Echocardiogr. 2011; 12: 790-797.
URL: https://www.ncbi.nlm.nih.gov/pubmed/21865229
9
Biederman RW, Magovern JA, Grant SB, Williams RB, Yamrozik JA, Vido DA, et al. Lv reverse remodeling imparted by aortic valve replacement for severe aortic stenosis; is it durable? A cardiovascular mri study sponsored by the american heart association. J Cardiothorac Surg. 2011; 6: 53.
URL: https://www.ncbi.nlm.nih.gov/pubmed/21492429
10
Monrad ES, Hess OM, Murakami T, Nonogi H, Corin WJ, Krayenbuehl HP. Time course of regression of left ventricular hypertrophy after aortic valve replacement. Circulation. 1988; 77: 1345-1355.
11
La Manna A, Sanfilippo A, Capodanno D, Antonella Salemi A, Cadoni A, Casckone I, et al. Left ventricular reverse remodeling after transcatheter aortic valve implantation: A cardiovascular magnetic resonance study. J Cardiovasc Magn Reson. 2013; 15: 39.
URL: https://jcmr-online.biomedcentral.com/articles/10.1186/1532-429X-15-39
12
Imanaka K, Kohmoto O, Nishimura S, Yokote Y, Kyo S. Impact of postoperative blood pressure control on regression of left ventricular mass following valve replacement for aortic stenosis. Eur J Cardiothorac Surg. 2005; 27: 994-999.
URL: https://www.ncbi.nlm.nih.gov/pubmed/15896607
13
Fielitz J, Leuschner M, Zurbrugg HR, Hannack B, Pregla R, Hetzer R, et al. Regulation of matrix metalloproteinases and their inhibitors in the left ventricular myocardium of patients with aortic stenosis. J Mol Med (Berl). 2004; 82: 809-820.
URL: https://www.ncbi.nlm.nih.gov/pubmed/15558223
14
Polyakova V, Hein S, Kostin S, Ziegelhoeffer T, Schaper J. Matrix metalloproteinases and their tissue inhibitors in pressure-overloaded human myocardium during heart failure progression. J Am Coll Cardiol. 2004; 44: 1609-1618.
URL: https://www.ncbi.nlm.nih.gov/pubmed/15489093
No Image

Author Name

Departments: